• Skip to main content

DistilGovHealth

DistilNFO GovHealth Advisory

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Illinois Passes Law Requiring Insurance Companies to Cover EpiPen Injections for Children in Historic First

Share:

August 21, 2019

Illinois Gov. J.B. Pritzker (D) has signed off on legislation making his state the first in the nation to require insurance companies to provide coverage for children who require life-saving EpiPen injections.

“I was proud to sign two new laws expanding insurance coverage for children whose allergies require live-saving EpiPens and Illinoisans suffering from Lyme disease,” the Illinois Democrat tweeted Tuesday.

“This legislation takes a big step forward in protecting our children and families,” he continued.

Under House Bill 3435, insurance companies are required to “provide coverage for medically necessary epinephrine injectors for persons 18 years of age or under.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The bill states that the law will apply to a “group or individual policy of accident and health insurance or a managed care plan that is amended, delivered, issued, or renewed” after the legislation takes effect starting in January 2020.

According to CNN, the bill makes Illinois the first state in the country to enact such legislation.

The maker of EpiPens, Mylan, has come under scrutiny in recent years for sharp price increases for the device.

Last year, the company paid a $465 million settlement following claims that it overcharged Medicaid for the emergency allergy treatment.

The FDA approved a generic competitor, from Teva Pharmaceuticals, to the original EpiPen in a move that many believed would help lead to lower costs for consumers last year.

However, to the shock of many, the generic drug did not cost less than the Mylan brand drug upon its release in November.

 
Date: August 21, 2019

Source: The Hill

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Divisions emerge over House drug price billsDivisions emerge over House drug price bills
  • World Health Organisation makes gaming addiction an official diseaseWorld Health Organisation makes gaming addiction an official disease
  • Government EHR proposals threaten patient privacyGovernment EHR proposals threaten patient privacy
  • As COVID-19 Cases Rise, No Time to Let Guard Down on PreventionAs COVID-19 Cases Rise, No Time to Let Guard Down on Prevention
  • As Democrats Talk Single Payer, Private Medicare Advantage SoarsAs Democrats Talk Single Payer, Private Medicare Advantage Soars
  • 66% Small, Medium Businesses Hit with Cyberattack in Past Year66% Small, Medium Businesses Hit with Cyberattack in Past Year

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications